Why do neuroprotective drugs work in animals but not humans?
1Stroke Branch, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Abstract:
Many neuroprotective agents that seemed promising in animal studies of ischemic brain injury prove to have no effect when tested in clinical trials, suggesting that fundamental elements of translational research require better definition. A number of modifications have led to improvements in preclinical and human studies since the earliest controlled trials failed to confirm hypotheses suggested by animal data. Continued re-evaluation and sharing of information derived from the laboratory bench or the patient's bedside should eventually lead to effective neuroprotection in acute stroke. Experimental data should be carefully studied to improve the quality of agents coming to clinical trials and to design trial phasing that effectively determines drug safety and efficacy. This article will examine preclinical modeling and its translation to prospective studies of acute stroke therapy and will focus on some potential solutions directed at clinical trial design.
Insights
Translational research for neuroprotection in ischemic stroke needs improvement. Better preclinical models and clinical trial designs are crucial for developing effective acute stroke therapies.
Area of Science:
- Neuroscience
- Neurology
- Translational Medicine
Background:
- Neuroprotective agents showing promise in animal models of ischemic brain injury often fail in human clinical trials.
- This discrepancy highlights a need for better definition and execution of translational research strategies.
Purpose of the Study:
- To examine the challenges in preclinical modeling for acute stroke therapy.
- To explore improvements in the translation of experimental data to clinical trials.
- To propose solutions for enhancing clinical trial design in stroke neuroprotection.
Main Methods:
- Review of preclinical models used in ischemic brain injury research.
- Analysis of factors contributing to the failure of neuroprotective agents in clinical trials.
- Examination of current and proposed clinical trial designs for acute stroke therapies.
Main Results:
- Existing preclinical models and translational approaches have limitations in predicting clinical efficacy.
- Modifications in study design and data sharing have shown some improvements.
- There is a critical need for higher quality experimental data and optimized trial phasing.
Conclusions:
- Effective neuroprotection in acute stroke requires rigorous re-evaluation of laboratory and clinical data.
- Improving the quality of agents entering clinical trials is essential.
- Optimized clinical trial design is key to accurately determining the safety and efficacy of neuroprotective drugs.
